Evidence mapPaperPMID 35213366Full record

Trial reportJournal of Alzheimer's disease : JAD2022

Short Term Economic Evaluation of the Digital Platform "Support, Monitoring and Reminder Technology for Mild Dementia" (SMART4MD) for People with Mild Cognitive Impairment and their Informal Caregivers.

Zartashia Ghani, Sanjib Saha, Johan Jarl, Martin Andersson, Johan Sanmartin Berglund, Peter Anderberg

Erratum issuedOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of Alzheimer's disease : JAD, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Zartashia GhaniApplied Health Technology, Department of Health, Blekinge Institute of Technology (BTH), Karlskrona, Sweden.
Sanjib SahaHealth Economics Unit, Department of Clinical Sciences (Malmö), Lund University, Lund, Sweden.
Johan JarlHealth Economics Unit, Department of Clinical Sciences (Malmö), Lund University, Lund, Sweden.
Martin AnderssonDepartment of Industrial Economics, Blekinge Institute of Technology (BTH), Karlskrona, Sweden.
Johan Sanmartin BerglundApplied Health Technology, Department of Health, Blekinge Institute of Technology (BTH), Karlskrona, Sweden.
Peter AnderbergApplied Health Technology, Department of Health, Blekinge Institute of Technology (BTH), Karlskrona, Sweden.
Blekinge Institute of Technology · SELund University · SEUniversity of Skövde · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA randomized controlled trial of the SMART4MD tablet application was conducted for persons with mild cognitive impairment (PwMCI) and their informal caregivers to improve or maintain quality of life.

objectiveThe objective was to conduct economic evaluation of SMART4MD compared to standard care in Sweden from a healthcare provider perspective based on a 6-month follow-up period.

methodsThree hundred forty-five dyads were enrolled: 173 dyads in the intervention group and 172 in standard care. The primary outcome measures for PwMCI and informal caregivers were quality-adjusted life years (QALY). The results are presented as incremental cost-effectiveness ratios, and confidence intervals are calculated using non-parametric bootstrap procedure.

resultsFor PwMCI, the mean difference in total costs between intervention and standard care was € 12 (95% CI: -2090 to 2115) (US$ = € 1.19) and the mean QALY change was -0.004 (95% CI: -0.009 to 0.002). For informal caregivers, the cost difference was - € 539 (95% CI: -2624 to 1545) and 0.003 (95% CI: -0.002 to 0.008) for QALY. The difference in cost and QALY for PwMCI and informal caregivers combined was -€ 527 (95% CI: -3621 to 2568) and -0.001 (95% CI: -0.008 to 0.006). Although generally insignificant differences, this indicates that SMART4MD, compared to standard care was: 1) more costly and less effective for PwMCI, 2) less costly and more effective for informal caregivers, and 3) less costly and less effective for PwMCI and informal caregivers combined.

conclusionThe cost-effectiveness of SMART4MD over 6 months is inconclusive, although the intervention might be more beneficial for informal caregivers than PwMCI.

Indexed as

Cognitive DysfunctionDementiaCaregiversCost-Benefit AnalysisHumansQuality of LifeTechnologyCarercost-effectivenesseconomic evaluationelderlymemorymHealthmild cognitive impairmentmild dementiamobile applicationsmartphone

Identifiers

PMID35213366
PMCPMC9108554
OpenAlexW4214694535

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.